Soja: ROSARIO
$481 -100.97%
Maíz: ROSARIO
$267,50 -0.89%
Trigo: ROSARIO
$291,30 -99.59%
By Agroempresario.com
Supergut, a startup in the rapidly growing GLP-1 nutrition category focused on digestive health, has made significant strides by securing a “significant growth equity investment” from Full Frame Growth Partners. Alongside this investment, the company has appointed Tracey Warner Halama, former CEO of Vital Proteins, as the new CEO to lead the next phase of growth for the brand.
Founded in 2020 by Marc Washington as 'Muniq,' Supergut specializes in powders, bars, and shakes containing a combination of resistant starches and prebiotic fibers. These ingredients are fermented in the gut, producing short-chain fatty acids, which are claimed to stimulate the production of appetite-suppressing gut hormones such as GLP-1, mimicking the effects of Ozempic-like drugs. Notably, Supergut is one of the few brands of its size with a peer-reviewed 12-week human clinical study that shows improved glycemic control and a slight reduction in body weight in volunteers with type 2 diabetes who consumed its products.
The company, which rebranded as Supergut in 2022, began as a direct-to-consumer business but has quickly expanded into retail, securing accounts with major retailers such as Erewhon, Target, Sprouts, GNC, and Vitamin Shoppe. This expansion, combined with the success of its ‘GLP-1 booster’ product, led to a 172% sales increase in 2024.
Halama, who previously played a pivotal role in growing Vital Proteins from a small startup into a multimillion-dollar brand that was acquired by Nestlé Health Science in 2021, stated that the new capital infusion would support product innovation, retail expansion, and hiring to meet the growing demand for Supergut’s products. Washington, now transitioning to an executive chairman role, will focus on strategic work rather than day-to-day operations, while Halama will take charge of managing the business on a daily basis.
Supergut’s success is not only due to its innovative products but also its ability to tap into the growing trend of GLP-1 nutrition, a category that has gained significant consumer attention. This is due in part to the increasing popularity of medications like Ozempic and the rising awareness of gut health’s role in overall wellness. Halama emphasized the unique opportunity Supergut has to capitalize on both trends, given the brand’s focus on accessible products powered by prebiotic fiber, which consumers can easily incorporate into their daily routines.
“Gut health and GLP-1 nutrition are two consumer megatrends that continue to pick up steam. Supergut is at the forefront of these movements with a leading brand and accessible products,” said Bader Alam of Full Frame Growth Partners, highlighting Supergut’s potential to dominate these growing markets.
Halama’s transition to Supergut came after her tenure at Full Frame Growth Partners, where she met startups like Supergut that were ahead of the curve in tapping into the GLP-1 trend. Halama was drawn to Supergut due to the brand’s scientific backing, including its clinical study—a rare asset for such a young company. This gave her confidence in the brand’s long-term potential and helped her to take on a role at the company as CEO.
Looking ahead, Halama’s focus will be on continuing to expand distribution, particularly with an emphasis on Amazon, while exploring new retail channels. Supergut’s products are now available in a variety of categories across retail stores, from the protein and meal replacement sections to digestive health and even emerging GLP-1 categories. This provides a broad appeal for Supergut’s products, whether consumers are looking for companion products to use with GLP-1 medications or alternatives for those who are unable to afford or tolerate them.
Halama also sees a significant opportunity for Supergut to help consumers experiencing digestive issues while taking GLP-1 drugs, or for those who are trying to reduce their dependence on these medications while maintaining control over cravings, blood sugar, and appetite. “We know people are using our products as a way to step down the off-ramp from GLP-1 medications,” she said, highlighting a key role for Supergut in the evolving market for digestive health.
Despite the success of Supergut, Halama acknowledges the potential risks associated with using the term “GLP-1 booster” on product packaging. While the brand’s clinical study didn’t specifically measure GLP-1 levels, it did show that participants with type 2 diabetes experienced improved glycemic control and modest weight loss. Halama is aware that the FDA may eventually require changes to marketing language, which could impact the way brands like Supergut advertise their products. As a result, the company has prepared contingency plans to pivot its messaging if needed.
“We are all navigating this space,” Halama explained. “That’s why we have a plan B in place in case we need to move on from this particular call-out on the packaging. We’ve already been through a clinical study, and we may conduct follow-up research in the future on the GLP-1 front.”
Ultimately, Halama’s vision for Supergut is to establish the company as the leader in digestive health. While the brand may explore opportunities in protein and general wellness, Halama emphasized that digestive health is the core of the Supergut brand and where the company plans to innovate. “We want to own the digestive health category. It’s not that we won’t explore other areas like protein or wellness, but fundamentally, our focus is on digestive health,” Halama stated.
Supergut aims to bridge the fiber gap, a significant issue in modern diets. The vast majority of people fail to consume the recommended 30 grams of fiber per day, and Supergut is positioning itself as the solution to this nutritional challenge.
When asked about Supergut’s potential, Halama was optimistic. “I think Supergut has the possibility to be well into the hundreds of millions of dollars in annual revenue,” she said, outlining the company’s long-term goals.
Founder Marc Washington, who continues to be deeply involved in Supergut’s strategic vision, remarked that while the brand isn’t comparable to Ozempic in terms of its impact, it plays a crucial role in shifting the conversation about how food can support the body’s natural mechanisms and metabolism. “Food is medicine, but it’s not Ozempic,” Washington said. “This is opening the avenue to have more of a conversation about your body’s natural mechanisms, metabolism, and how everything is connected to your gut microbiome.”
Washington also highlighted the broader benefits of consuming a mix of prebiotic fibers, including improvements in gut health and metabolic function, as well as their role in controlling appetite and supporting weight loss. He pointed out that resistant starch—a long-overlooked ingredient in nutrition science—is finally getting the attention it deserves as a key component of metabolic health.
With the growing focus on gut health and GLP-1 nutrition, Supergut is poised to lead the charge in an exciting and rapidly expanding market, making strides toward becoming a dominant player in the digestive health category.
